Richard A. Paulson Sells 3,479 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock

Karyopharm Therapeutics Inc. (NASDAQ:KPTIGet Rating) CEO Richard A. Paulson sold 3,479 shares of the firm’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $5.23, for a total transaction of $18,195.17. Following the completion of the sale, the chief executive officer now directly owns 622,998 shares in the company, valued at approximately $3,258,279.54. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Karyopharm Therapeutics Price Performance

NASDAQ:KPTI opened at $5.35 on Friday. Karyopharm Therapeutics Inc. has a one year low of $4.00 and a one year high of $14.73. The company’s 50-day simple moving average is $5.00 and its 200 day simple moving average is $5.95. The firm has a market capitalization of $426.98 million, a P/E ratio of -3.88 and a beta of -0.03.

Karyopharm Therapeutics (NASDAQ:KPTIGet Rating) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.01. The business had revenue of $39.68 million for the quarter, compared to the consensus estimate of $36.38 million. On average, equities research analysts expect that Karyopharm Therapeutics Inc. will post -2.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Barclays cut their price target on shares of Karyopharm Therapeutics from $14.00 to $8.00 and set an “overweight” rating on the stock in a report on Friday, August 5th. Robert W. Baird cut their target price on shares of Karyopharm Therapeutics from $17.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, August 5th. Morgan Stanley cut their target price on shares of Karyopharm Therapeutics from $10.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Friday. Finally, HC Wainwright cut their target price on shares of Karyopharm Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, August 5th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Karyopharm Therapeutics has a consensus rating of “Hold” and an average price target of $9.88.

Institutional Investors Weigh In On Karyopharm Therapeutics

Hedge funds have recently bought and sold shares of the business. IndexIQ Advisors LLC bought a new stake in Karyopharm Therapeutics during the first quarter worth about $394,000. Northern Trust Corp raised its holdings in Karyopharm Therapeutics by 1.1% in the fourth quarter. Northern Trust Corp now owns 775,551 shares of the company’s stock worth $4,986,000 after buying an additional 8,491 shares during the last quarter. Baird Financial Group Inc. raised its holdings in Karyopharm Therapeutics by 12.1% in the fourth quarter. Baird Financial Group Inc. now owns 19,817 shares of the company’s stock worth $127,000 after buying an additional 2,137 shares during the last quarter. Running Point Capital Advisors LLC purchased a new position in Karyopharm Therapeutics in the first quarter worth about $74,000. Finally, Teacher Retirement System of Texas purchased a new position in Karyopharm Therapeutics in the fourth quarter worth about $84,000. Institutional investors own 84.66% of the company’s stock.

Karyopharm Therapeutics Company Profile

(Get Rating)

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.

Further Reading

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.